Results 291 to 300 of about 1,353,045 (362)

FOXM1 Protects Against Myocardial Ischemia‐Reperfusion Injury in Rodent and Porcine Models by Suppressing MKRN1‐Dependent LKB1 Ubiquitination

Advanced Science, EarlyView.
FOXM1 maintains mitochondrial bioenergetic function by inhibiting MKRN1‐mediated ubiquitination of LKB1 in cardiomyocytes. Loss of FOXM1 in cardiomyocytes results in upregulation of MKRN1, which enhances LKB1 ubiquitination and disrupts AMPK signaling and energy metabolism pathways. Conversely, FOXM1 overexpression preserves mitochondrial bioenergetics
Shuai Song, Xiaokai Zhang, Zihang Huang, Zhiqiang Pei, Linqi Zeng, Fengze Cai, Tongyao Wang, Mohan Li, Chenyan Liu, Yining Song, Jiahao Guo, Hao Lu, Xinyu Weng, Li Shen, Xiaochun Zhang, Xingxing Cai, Aijun Sun, Junbo Ge   +17 more
wiley   +1 more source

Using circular RNAs to target toxic RNA-binding proteins in amyotrophic lateral sclerosis. [PDF]

Mol Ther Methods Clin Dev
Hollensen AK, Sørensen MH, Thomsen SV, Thomsen HS, Damgaard CK.   +4 more
europepmc   +1 more source

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

Advanced Science, EarlyView.
Relapsed and refractory multiple myeloma remains a major clinical challenge. This study shows that FOXM1 contributes to resistance against BH3 mimetics in multiple myeloma cells. The FOXM1 inhibitor NB73 enhances the effectiveness of BH3 mimetics by reducing FOXM1 expression and suppressing the MYC pathway.
Zhi Wen, Yidan Wang, Kathryn C. Fox, Adam M. Bissonnette, Luke F. Moat, Terrie E. Kitchner, Kelsey Springstroh, Sung Hoon Kim, Dagna S. Sheerar, Patcharon Tanawattanacharoen, Chady A. Leon, Seth O. Fagbemi, John A. Katzenellenbogen, Scott J. Hebbring, Benita S. Katzenellenbogen, Siegfried Janz, Adedayo A. Onitilo   +16 more
wiley   +1 more source

Mixed Lineage Kinase Domain‐Like Protein (MLKL): From Mechanisms to Therapeutic Opportunities

Advanced Science, EarlyView.
The mixed lineage kinase domain‐like protein (MLKL) acts as the executioner in the necroptosis pathway, transitioning from an inactive to active state through phosphorylation, oligomerization, membrane recruitment, and membrane insertion, ultimately forming membrane hotpots.
Lijuan Xu, Chunlin Zhuang
wiley   +1 more source

Circular RNAs as Targets for Developing Anticancer Therapeutics. [PDF]

Cells
Jeoung J, Kim W, Jo H, Jeoung D.
europepmc   +1 more source

A Charge‐Adhesive Targeted DNA Gel Bandage for the Precision Treatment of Inflammatory Bowel Disease

Advanced Science, EarlyView.
DNA gel bandage (DNAgb) is designed to precisely target the site of inflammation of IBD, by achieving dual specific localization of inflamed mucosa through electrostatic interactions and ApITGA4‐mediated affinity targeting. DNAgb effectively the activation of inflammatory pathways and reshapes the immune microenvironment.
Peifen Lu, Hongxiu Yuan, Gang Wang, Tao Cheng, Lie Li, Yixi Dong, Runyu Zhao, Xuerui Zhang, Jianwei Jiao, Jin Jiao   +9 more
wiley   +1 more source

Biomolecular Interaction Prediction: The Era of AI

Advanced Science, EarlyView.
This review offers a thorough examination of recent progress in deep learning for predicting biomolecular interactions, including those involving proteins, nucleic acids, and small molecules. It covers data processing strategies, representative model architectures, and evaluation metrics, while highlighting current methodological limitations.
Haoping Wang, Xiangjie Meng, Yang Zhang
wiley   +1 more source

Role of MEX3A in tumorigenesis: Mechanisms, tumor‑specific effects and therapeutic implications (Review). [PDF]

Int J Mol Med
Tang L, Zhang L, Yao S, Li X, Wang Y, Liu Q, Li J, Wen G, An J, Jin H, Zhu J, Tuo B.   +11 more
europepmc   +1 more source

Mechanism of Lenvatinib Resistance via Exosomal miRNA‐132/Nrf2 Axis in Hepatocellular Carcinoma

Annals of Gastroenterological Surgery, EarlyView.
Exosomal miRNA‐132 from LVT‐res HCC cells activated Nrf2 expression through the PTEN/GSK3β pathway in recipient cells. This cascade could induce drug resistance in non‐resistant HCC cells in the TME. ABSTRACT Introduction Lenvatinib is a multiple receptor tyrosine kinase inhibitor and a first‐line targeted therapy for hepatocellular carcinoma (HCC ...
Chie Takasu, Chiharu Nakasu, Yu Saito, Yuji Morine, Tetsuya Ikemoto, Shinichiro Yamada, Hiroki Teraoku, Mitsuo Shimada   +7 more
wiley   +1 more source